微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 47.9% | -0.99% | -2.47% | 81/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 49.12% | 3.07% | 1.82% | 77/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 48.24% | 7.38% | -1.34% | 76/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 48.9% | 8.54% | 1.06% | 74/157 | 14.83% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 48.38% | 6.4% | 1.54% | 72/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 47.65% | 1.21% | 6.07% | 83/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 44.92% | -0.54% | -0.28% | 87/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 45.05% | -6.2% | -0.93% | 88/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 45.47% | -3.1% | -3.42% | 84/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 47.08% | -16.78% | 4.24% | 85/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 45.17% | -18.99% | -5.96% | 92/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 48.03% | -16.24% | 2.35% | 84/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 46.93% | -23.85% | -17.05% | 84/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 56.57% | 37.1% | 1.47% | 69/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 55.75% | 44.78% | -2.77% | 66/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 57.34% | 61.81% | -6.95% | 66/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 61.62% | 96.39% | 49.34% | 52/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 41.26% | 41.83% | 7.15% | 96/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 38.51% | 37.99% | 8.67% | 97/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 35.44% | 19.36% | 12.94% | 110/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 31.38% | 2.62% | 7.85% | 102/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 29.09% | 3.62% | 4.25% | 127/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 27.91% | 5.04% | -5.99% | 107/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 29.69% | 4.47% | -2.9% | 114/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 30.58% | 12.28% | 8.9% | 94/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 28.08% | -2.11% | 5.68% | 120/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 26.57% | -1.52% | -6.5% | 96/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 28.42% | 3.84% | 4.35% | 101/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 27.23% | 3.61% | -5.06% | 94/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 28.68% | -5.01% | 6.32% | 118/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 26.98% | -10.69% | -1.42% | 91/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 27.37% | -10.12% | 4.13% | 96/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 26.28% | 2% | -12.96% | 91/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 30.2% | 2.93% | -0.03% | 104/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 30.21% | 2% | -0.8% | 76/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 30.45% | 2% | 3.79% | 79/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 29.34% | 1.17% | 1.17% | 89/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |